FDA Reviewers Share CMC, GMP Challenges In Last Year's Rush To Approve New Therapies

Inundated with high-priority applications last year, US FDA's CMC reviewers struggled with seemingly thrown-together review packages, moving-target manufacturing processes and not-on-the-same-page contract manufacturers.